<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.vascularcell.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Vascular Cell - Latest Articles</title>
        <link>http://www.vascularcell.com</link>
        <description>The latest research articles published by Vascular Cell</description>
        <dc:date>2012-05-15T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/10" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/9" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/8" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/7" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/6" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/5" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/4" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/3" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/2" />
                                <rdf:li rdf:resource="http://www.vascularcell.com/content/4/1/1" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.vascularcell.com/content/4/1/10">
        <title>The Angiogenic Response is Dependent on Ultrasound Contrast Agent Concentration</title>
        <description>ObjectiveUltrasound (US) and ultrasound contrast agents (UCAs) provide a way to noninvasively and spatially induce angiogenesis.  However there exists a lack of understanding regarding the mechanisms of this process that has suppressed progress. This study sought to characterize the angiogenic response, by exploring the role of UCA concentration ([UCA]) in bioeffect induction at 0 days post exposure (DPE) and as a possible potentiator of angiogenesis at 5 DPE.
Methods:
A 1-MHz transducer was used to expose the gracilis muscles of Sprague Dawley rats for a 5 min exposure duration with a 10-us pulse duration, 10-Hz pulse repetition frequency, and 0.7-MPa peak rarefactional acoustic pressure (pr). Four [UCA]s were tested: 0x (saline), 1x, 5x, and 10x, where 1x is 5% Definity by volume of solution.  Evans blue dye (EBD) was used to quantify acute vascular permeability (0 DPE), and VEGF expression was quantified at 5 DPE to support that angiogenesis had occurred.  CD31 staining was used to assess capillary density at both time points.
Results:
This study showed that [UCA] was a significant parameter for determining EBD leakage (permeability) and VEGF expression (p &lt; 0.001 for both). However, [UCA] was not a significant parameter for capillary density at 0 or 5 DPE.  Multiple comparisons between 0 and 5 DPE showed that only 10x [UCA] at 5 DPE was significantly different than 0 DPE suggesting a [UCA] dependence of the angiogenic response.
Conclusion:
This study suggests that [UCA] is a significant parameter in the induction of an angiogenic response with US and UCAs.  It also suggests that mechanically induced bioeffects could potentiate the angiogenic response.</description>
        <link>http://www.vascularcell.com/content/4/1/10</link>
                <dc:creator>Chenara Johnson</dc:creator>
                <dc:creator>William O'Brien</dc:creator>
                <dc:source>Vascular Cell 2012, null:10</dc:source>
        <dc:date>2012-05-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-10</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-10-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-05-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/9">
        <title>Unique vascular protective properties of natural 
products: supplements or future main-line drugs 
with significant anti-atherosclerotic potential? </title>
        <description>Natural health products (NHP) which include minerals, vitamins and herbal remedies are notgenerally considered by medical practitioners as conventional medicines and as such are notfrequently prescribed by health centre&apos;s as either main-line or supplemental treatments. In thefield of cardiovascular medicine, studies have shown that typically, less than half of patientssuffering from coronary syndromes chose to take any form of NHP supplement and theseproducts are rarely recommended by their medical practitioner. Vascular/endothelial celldamage is a key instigator of coronary arterial plaque development which often culminates inthrombosis and myocardial infarction (MI). Current treatment for patients known to be at riskof primary or secondary (MI) includes lipid lowering statins, anti-clotting agents (e.g. tissueplasminogen activator; tPA) and drugs for stabilization of blood pressure such as betablockers. However, evidence has been building which suggests that components of at least several NHP (e.g. aged garlic extract (AGExt), resveratrol and green tea extracts (GTE)) may have significant vascular protective effects through reduction of oxidative stress, lowering of blood pressure, reduction in platelet aggregation, vasodilation and inhibition of abnormal angiogenesis. Therefore, in this review we will discuss in detail the potential of these substances (chosen on the basis of their potency and complimentarity) as anti-atherosclerotic agents and the justification for their consideration as main-line additional supplements or prescriptions.</description>
        <link>http://www.vascularcell.com/content/4/1/9</link>
                <dc:creator>mark slevin</dc:creator>
                <dc:creator>Nessar Ahmed</dc:creator>
                <dc:creator>Quiyu Wang</dc:creator>
                <dc:creator>Garry Mcdowell</dc:creator>
                <dc:creator>Lina Badimon</dc:creator>
                <dc:source>Vascular Cell 2012, null:9</dc:source>
        <dc:date>2012-04-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-9</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-9-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2012-04-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/8">
        <title>Angiogenic efficacy of Heparin on chick chorioallantoic membrane</title>
        <description>Heparin is an anticoagulant agent known to have diverse effects on angiogenesis with some reports suggesting that it can induce angiogenesis while a few have indicated of its inhibitory property. Cancer patients treated for venous thromboembolism with low molecular heparin had a better survival than the unfractionated heparin (UFH). Heparin is known to interact with various angiogenic growth factors based on its sulfation modifications within the glycosaminoglycan chains Therefore it is important to study the mechanism of action of heparin of different molecular weight to understand its angiogenic property. In this concern we examined the angiogenic response of higher molecular weight Heparin (15 kDa) of different concentrations using late CAM assay. Growth of blood vessels in terms of their length and size was measured and thickness of the CAM was calculated morphometrically. The observed increase in the thickness of the CAM is suggestive of the formation of capillary like structures at the treated region. Analysis of the diffusion pattern showed internalized action of heparin that could affect gene expression leading to proliferation of endothelial cells. Angiogenesis refers to formation of new blood vessels from the existing ones and occurrence of new blood vessels at the treated area strongly confirms that heparin of 15 kDa molecular weight has the ability to induce angiogenesis on CAM vascular bed in a dose dependent manner. The results demonstrate the affinity of heparin to induce angiogenesis and provide a novel mechanism by which heparin could be used in therapeutics such as in wound healing process.</description>
        <link>http://www.vascularcell.com/content/4/1/8</link>
                <dc:creator>Reji Bhuvanendran Rema</dc:creator>
                <dc:creator>Karthick Rajendran</dc:creator>
                <dc:creator>Malathi Ragunathan</dc:creator>
                <dc:source>Vascular Cell 2012, null:8</dc:source>
        <dc:date>2012-04-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-8</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-8-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2012-04-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/7">
        <title>Notch Signals In The Endothelium And Cancer &quot;Stem-like&quot; Cells: Opportunities For Cancer Therapy
</title>
        <description>Anti-angiogenesis agents and the identification of cancer stem-like cells (CSC) are opening new avenues for targeted cancer therapy. Recent evidence indicates that angiogenesis regulatory pathways and developmental pathways that control CSC fate are intimately connected, and that endothelial cells are a key component of the CSC niche. Numerous anti-angiogenic therapies developed so far target the VEGF pathway. However, VEGF-targeted therapy is hindered by clinical resistance and side effects, and new approaches are needed. One such approach may be direct targeting of tumor endothelial cell fate determination. Interfering with tumor endothelial cells growth and survival could inhibit not only angiogenesis but also the self-replication of CSC, which relies on signals from surrounding endothelial cells in the tumor microenvironment. The Notch pathway is central to controlling cell fate both during angiogenesis and in CSC from several tumors. A number of investigational Notch inhibitors are being developed. Understanding how Notch interacts with other factors that control endothelial cell functions and angiogenesis in cancers could pave the way to innovative therapeutic strategies that simultaneously target angiogenesis and CSC.</description>
        <link>http://www.vascularcell.com/content/4/1/7</link>
                <dc:creator>Jian-Wei Gu</dc:creator>
                <dc:creator>Paola Rizzo</dc:creator>
                <dc:creator>Antonio Pannuti</dc:creator>
                <dc:creator>Todd Golde</dc:creator>
                <dc:creator>Barbara Osborne</dc:creator>
                <dc:creator>Lucio Miele</dc:creator>
                <dc:source>Vascular Cell 2012, null:7</dc:source>
        <dc:date>2012-04-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-7</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-7-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-04-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/6">
        <title>Correction: Co-culture of retinal and endothelial cells results in the modulation of genes critical to retinal neovascularization</title>
        <description>Following publication of our article (Kumar et al, Vascular Cell, 2011, 3: 27) it was noted that Figures five E and five G were the same as Figures six A and six B. Figure 1 in this correction article is the correct version of Figure six that should have been included in the original article (Kumar et al, Vascular Cell, 2011, 3: 27). We apologize for any inconvenience caused by this error.</description>
        <link>http://www.vascularcell.com/content/4/1/6</link>
                <dc:creator>Ravindra Kumar</dc:creator>
                <dc:creator>Sandra Harris-Hooker</dc:creator>
                <dc:creator>Ritesh Kumar</dc:creator>
                <dc:creator>Gary Sanford</dc:creator>
                <dc:source>Vascular Cell 2012, null:6</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-6</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-6-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/5">
        <title>Positron emission tomography detection of human endothelial cell and fibroblast monolayers: effect of pretreament and cell density on 18FDG uptake</title>
        <description>Background:
The non-destructive assessment and characterization of tridimensional (3D) cell and tissue constructs in bioreactors represents a challenge in tissue engineering. Medical imaging modalities, which can provide information on the structure and function of internal organs and tissues in living organisms, have the potential of allowing repetitive monitoring of these 3D cultures in vitro. Positron emission tomography (PET) is the most sensitive non-invasive imaging modality, capable of measuring picomolar amounts of radiolabeled molecules. However, since PET imaging protocols have been designed almost exclusively for in vivo investigations, suitable methods must be devised to enable imaging of cells or tissue substitutes. As a prior step to imaging 3D cultures, cell radiotracer uptake conditions must first be optimized.
Methods:
In this study, human umbilical vein endothelial cells (HUVEC) and human fibroblasts were cultured at different densities and PET was used to non-destructively monitor their glycolytic activity by measuring 18F-fluorodeoxyglucose (18FDG) uptake. Various cell preconditioning protocols were investigated by adjusting the following parameters to optimize 18FDG uptake: glucose starvation, insulin stimulation, glucose concentration, 18FDG incubation time, cell density and radiotracer efflux prevention.
Results:
The conditions yielding optimal 18FDG uptake, and hence best detection sensitivity by PET, were as follows: 2-hour cell preconditioning by glucose deprivation with 1-hour insulin stimulation, followed by 1-hour 18FDG incubation and 15-minute stabilization in standard culture medium, prior to rinsing and PET scanning.
Conclusions:
A step-wise dependence of 18FDG uptake on glucose concentration was found, but a linear correlation between PET signal and cell density was observed. Detection thresholds of 36 &#177; 7 and 21 &#177; 4 cells were estimated for endothelial cells and fibroblasts, respectively.</description>
        <link>http://www.vascularcell.com/content/4/1/5</link>
                <dc:creator>Julie Chouinard</dc:creator>
                <dc:creator>Jacques Rousseau</dc:creator>
                <dc:creator>Jean-Francois Beaudoin</dc:creator>
                <dc:creator>Patrick Vermette</dc:creator>
                <dc:creator>Roger Lecomte</dc:creator>
                <dc:source>Vascular Cell 2012, null:5</dc:source>
        <dc:date>2012-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-5</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-5-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/4">
        <title>Pleiotrophin expression and role in physiological angiogenesis in vivo: Potential involvement of nucleolin</title>
        <description>Background:
Pleiotrophin (PTN) is a heparin-binding growth factor with significant role(s) in tumour growth and angiogenesis. Although implication of endogenous PTN has been studied in several in vivo models of tumour angiogenesis, its role in physiological angiogenesis has not been addressed. In the present work, we studied expression and functional significance of endogenous PTN during angiogenesis in the chicken embryo chorioallantoic membrane (CAM).
Methods:
Using molecular, cellular and biochemical assays, we studied the expression pattern of PTN in CAM and human endothelial cells and its possible interaction with nucleolin (NCL). CAM cells were transfected with a pCDNA3.1 vector, empty (PC) or containing full length cDNA for PTN in antisense orientation (AS-PTN). Angiogenesis was estimated by measuring total vessel length. In vitro, human endothelial cells migration was studied by using a transwell assay, and down-regulation of NCL was performed by using a proper siRNA.
Results:
Endogenous PTN mRNA and protein levels, as well as protein levels of its receptor protein tyrosine phosphatase beta/zeta (RPTPbeta/zeta) were maximal at early stages, when CAM angiogenesis is active. Application of AS-PTN onto CAM at days of active angiogenesis was not toxic to the tissue and led to dose-dependent decreased expression of endogenous PTN, ERK1/2 activity and angiogenesis. Interestingly, endogenous PTN was also immunolocalized at the endothelial cell nucleus, possibly through interaction with NCL, a protein that has a significant role in the nuclear translocation of many proteins. Down-regulation of NCL by siRNA in human endothelial cells significantly decreased nuclear PTN, verifying this hypothesis. Moreover, it led to abolishment of PTN-induced endothelial cell migration, suggesting, for the first time, that PTN-NCL interaction has a functional significance.
Conclusions:
Expression of endogenous PTN correlates with and seems to be involved in angiogenesis of the chicken embryo CAM. Our data suggest that NCL may have a role, increasing the number of growth factors whose angiogenic/tumorigenic activities are mediated by NCL.</description>
        <link>http://www.vascularcell.com/content/4/1/4</link>
                <dc:creator>Marina Koutsioumpa</dc:creator>
                <dc:creator>Georgia Drosou</dc:creator>
                <dc:creator>Constantinos Mikelis</dc:creator>
                <dc:creator>Katerina Theochari</dc:creator>
                <dc:creator>Dionussios Vourtsis</dc:creator>
                <dc:creator>Panagiotis Katsoris</dc:creator>
                <dc:creator>Efstathia Giannopoulou</dc:creator>
                <dc:creator>Jose Courty</dc:creator>
                <dc:creator>Christos Petrou</dc:creator>
                <dc:creator>Vassiliki Magafa</dc:creator>
                <dc:creator>Paul Cordopatis</dc:creator>
                <dc:creator>Evangelia Papadimitriou</dc:creator>
                <dc:source>Vascular Cell 2012, null:4</dc:source>
        <dc:date>2012-03-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-4</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-4-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-03-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/3">
        <title>Specific tumor-stroma interactions of EBV-positive Burkitt&apos;s lymphoma cells in the chick chorioallantoic membrane</title>
        <description>Background:
Burkitt&apos;s lymphoma (BL) is an aggressive Non-Hodgkin lymphoma. Epstein-Barr Virus (EBV) is able to transform B cells and is a causative infectious agent in BL. The precise role of EBV in lymphoma progression is still unclear. Most investigations have concentrated on cell autonomous functions of EBV in B cells. Functions of the local environment in BL progression have rarely been studied, mainly due to the lack of appropriate in vivo models. Therefore, we inoculated different human BL cell-lines onto the chorioallantoic membrane (CAM) of embryonic day 10 (ED10) chick embryos and re-incubated until ED14 and ED17.
Results:
All cell-lines formed solid tumors. However, we observed strong differences in the behavior of EBV+ and EBV- cell-lines. Tumor borders of EBV+ cells were very fuzzy and numerous cells migrated into the CAM. In EBV- tumors, the borders were much better defined. In contrast to EBV- cells, the EBV+ cells induced massive immigration of chick leukocytes at the tumor borders and the development of granulation tissue with large numbers of blood vessels and lymphatics, although the expression of pro- and anti-angiogenic forms of Vascular Endothelial Growth Factors/receptors was the same in all BL cell-lines tested. The EBV+ cell-lines massively disseminated via the lymphatics and completely occluded them.
Conclusions:
Our data suggest that the EBV+ cells attract pro-angiogenic leukocytes, which then induce secondary tumor-stroma interactions contributing to the progression of BL. We show that the CAM is a highly suitable in vivo model to study the differential behavior of BL cell-lines.</description>
        <link>http://www.vascularcell.com/content/4/1/3</link>
                <dc:creator>Juergen Becker</dc:creator>
                <dc:creator>Ana Covelo-Fernandez</dc:creator>
                <dc:creator>Frederike von Bonin</dc:creator>
                <dc:creator>Dieter Kube</dc:creator>
                <dc:creator>Joerg Wilting</dc:creator>
                <dc:source>Vascular Cell 2012, null:3</dc:source>
        <dc:date>2012-03-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-3</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-3-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-03-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/2">
        <title>Polysaccharides from astragali radix restore chemical-induced blood vessel loss in zebrafish</title>
        <description>Background:
Astragali Radix has been used widely for the treatment of cardiovascular and cerebrovascular diseases, and to enhance endurance and stamina in traditional Chinese medicine (TCM) for over 2000 years. The polysaccharide constituents of Astragali Radix (ARP) are considered as one of the major constituents contributing to the multiple pharmacological effects of this medicinal plant. The purpose of the study is to evaluate the vascular regenerative activities of ARPs in a chemically-induced blood vessel loss model in zebrafish.
Methods:
Blood vessel loss was induced in both Tg(fli-1a:EGFP)y1 and Tg(fli-1a:nEGFP)y7 embryos by administration of 300 nM VEGFR tyrosine kinase inhibitor II (VRI) for 3 h at 24 hpf (hour post-fertilization). Then, the blood vessel damaged zebrafish were treated with ARPs for 21 h and 45 h after VRI withdrawal. Morphological changes in intersegmental vessels (ISVs) of zebrafish larvae were observed under the fluorescence microscope and measured quantitatively. The rescue effect of ARPs in the zebrafish models was validated by measuring the relative mRNA expressions of Kdrl, Kdr and Flt-1 using real-time PCR.
Results:
Two polysaccharide fractions, P4 (50000 D &lt; molecular weight &amp; diameter &lt; 0.1 &#956;m) and P5 (molecular diameter &gt; 0.1 &#956;m), isolated from Astragali Radix by ultrafiltration, produced a significant and dose-dependent recovery in VRI-induced blood vessel loss in zebrafish. Furthermore, the down-regulation of Flk-1 and Flt-1 mRNA expression induced by VRI was reversed by treatment with P4.
Conclusion:
The present study demonstrates that P4 isolated from Astragali Radix reduces VRI-induced blood vessel loss in zebrafish. These findings support the hypothesis that polysaccharides are one of the active constituents in Astragali Radix, contributing to its beneficial effect on treatment of diseases associated with a deficiency in angiogenesis.</description>
        <link>http://www.vascularcell.com/content/4/1/2</link>
                <dc:creator>Guang Hu</dc:creator>
                <dc:creator>Gail Mahady</dc:creator>
                <dc:creator>Shang Li</dc:creator>
                <dc:creator>Maggie Pui Man Hoi</dc:creator>
                <dc:creator>You Hua Wang</dc:creator>
                <dc:creator>Simon Ming Yuen Lee</dc:creator>
                <dc:source>Vascular Cell 2012, null:2</dc:source>
        <dc:date>2012-02-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-2</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-2-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-02-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.vascularcell.com/content/4/1/1">
        <title>RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA</title>
        <description>Recent studies have suggested a role for the small GTPase RhoB in the control of processes required for angiogenesis. However, the mechanisms whereby RhoB exerts control over these processes are not well understood. Given the role of vascular endothelial growth factor (VEGF) in pathological angiogenesis, we were interested in examining whether RhoB contributed to VEGF-induced angiogenic processes. To assess this, RhoB was specifically depleted in human umbilical vein endothelial cells (HUVEC), using siRNA-targeted strategies. The effects of RhoB depletion on VEGF-induced angiogenic activities were assessed using a variety of standard in vitro angiogenesis assays to assess endothelial cell viability, migration and capillary morphogenesis. Effects of RhoB depletion on signaling from other Rho family member proteins was also assessed using specific activity assays for RhoA and RhoC. We observed that although RhoB appeared dispensable for HUVEC viability, RhoB was required for endothelial cell migration, sprouting, and capillary morphogenesis. We also observed that siRNA-mediated depletion of RhoB in HUVEC resulted in increased RhoA activation in response to VEGF stimulation. This increased RhoA activation contributed to the cellular morphogenesis defects observed in RhoB-depleted cells, as inhibition of RhoA activity using C3 transferase, or inhibition of the activity of the downstream RhoA effectors Rho-dependent kinases I and II (ROCK I and II) led to a partial restoration of capillary morphogenesis in the absence of RhoB. Thus our data indicate that RhoB plays a significant role in VEGF-induced endothelial cell morphogenesis in part by negatively regulating the activity of RhoA and the RhoA/ROCK pathway.</description>
        <link>http://www.vascularcell.com/content/4/1/1</link>
                <dc:creator>Grant Howe</dc:creator>
                <dc:creator>Christina Addison</dc:creator>
                <dc:source>Vascular Cell 2012, null:1</dc:source>
        <dc:date>2012-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2045-824X-4-1</dc:identifier>
                                <prism:require>/content/figures/2045-824X-4-1-toc.gif</prism:require>
                <prism:publicationName>Vascular Cell</prism:publicationName>
        <prism:issn>2045-824X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

